Prognoza

Nie mamy danych analityków dla tej spółki.

Wiadomości Przejdź do aktualności

SenzaGen achieves 13% revenue growth in second quarter thanks to recovery at VitroScreen

SenzaGen reports a 13% increase in revenue in the second quarter to SEK 15.3 million, driven by a recovery at subsidiary VitroScreen and two large orders. The operating loss narrowed, earnings per share improved compared with the previous year, and operating cash flow was positive. The company maintained a stable gross margin, cited effective cost management, and expects EU regulations reducing animal testing to support long-term demand for its test solutions. » Więcej na de.investing.com

W ostatnim kwartale SENZAGEN AB osiągnęła przychody w wysokości 1,38 mln € i zysk netto w wysokości -200,15 tys. €